Praluent Manufacturer Bridge Programs: How to Get Alirocumab Cheaper in 2026

What Is a Manufacturer Bridge Program for Praluent?

A bridge program provides short-term, free, or heavily discounted drug supply while a patient's insurance prior authorization is being processed, appealed, or re-evaluated. For Praluent, Regeneron and Sanofi operate this through their Praluent360 patient support hub. The program typically covers 30 to 90 days of medication at no cost to the patient.

Why PCSK9 Inhibitors Require Bridge Coverage

Prior authorization denial rates for PCSK9 inhibitors remain high. A 2019 JAMA Cardiology analysis found that among patients prescribed a PCSK9 inhibitor, only 54.6% had their prescription filled within 90 days, largely because of insurance barriers 1. Without a bridge, patients face a treatment gap that could raise LDL-C and increase cardiovascular risk. The ACC/AHA 2019 Guideline on the Primary Prevention of Cardiovascular Disease explicitly states that "for patients in whom a statin is indicated, statins reduce ASCVD events" and supports adjunct lipid-lowering when LDL-C targets are not met on statin therapy alone 2.

How Alirocumab Works and Why Cost Matters

Alirocumab binds proprotein convertase subtilisin/kexin type 9 (PCSK9) and prevents it from degrading LDL receptors on hepatocytes, which lowers circulating LDL-C by 45 to 60% 3. In ODYSSEY OUTCOMES (N=18,924), alirocumab 75 to 150 mg every 2 weeks reduced the composite MACE endpoint by 15% relative to placebo (HR 0.85, 95% CI 0.78 to 0.93, P<0.001) over a median follow-up of 2.8 years 4. The clinical benefit is well-established. The barrier is almost always cost, which makes manufacturer programs the first line of access strategy for most prescribers.

The Praluent Copay Savings Card: How It Works

Commercially insured patients who are not enrolled in a government-funded plan (Medicare, Medicaid, TRICARE, or any federal or state program) may qualify for the Praluent copay card, which can reduce monthly out-of-pocket costs to $0. The card is valid at most retail pharmacies and through specialty pharmacy channels.

Eligibility Requirements

The copay card applies only to patients with commercial insurance. Patients enrolled in Medicare Part D, Medicaid, or any government-sponsored plan are explicitly excluded by Sanofi/Regeneron program terms. The card has no stated income limit for commercially insured patients, which means even high-income patients can use it as long as they have private coverage. The offer typically caps total manufacturer savings at a set annual amount; historically this has been approximately $3,600 per year, though program details change and should be verified directly at PraluentPro.com or by calling Praluent360 at 1-844-PRALUENT.

How to Enroll

Enrollment takes three steps. First, confirm commercial insurance coverage with your prescriber or pharmacist. Second, download the savings card from the Regeneron/Sanofi Praluent support site or have your prescriber enroll you through the electronic hub. Third, present the card at your specialty pharmacy at pickup. Most specialty pharmacies that dispense Praluent, including CVS Specialty and Walgreens Specialty, accept the card directly in their billing system.

What the Card Does Not Cover

The copay card does not reduce the insurer's portion of the drug cost. It reduces only the patient cost-sharing layer. Patients who have not yet met their deductible may find the card covers a significant portion of the deductible-phase cost, but the card's annual maximum may be exhausted before the calendar year ends if deductible exposure is large 5.

The Praluent Patient Assistance Program (PAP)

For patients without insurance or whose insurance does not cover Praluent after all appeals are exhausted, Sanofi offers a PAP through its Sanofi Patient Connection program. The PAP provides alirocumab at no cost to qualifying patients.

Income Thresholds and Documentation

The PAP income threshold is generally set at or below 400% of the Federal Poverty Level (FPL). For a single-person household in 2025, 400% FPL is approximately $62,520 per year. For a family of four, the threshold rises to approximately $127,080 6. Patients must submit proof of income (tax return, W-2, or pay stubs), proof of residence, a completed enrollment form, and a signed prescription from their physician. Processing typically takes 2 to 4 weeks. During that window, the bridge program (see below) may provide interim supply.

How Long the PAP Covers Treatment

Approved PAP applications typically provide a 90-day supply initially, with renewals every 12 months contingent on income re-verification. Some patients remain on PAP for several years if their financial situation does not change. A 2022 analysis published in the Journal of the American Heart Association found that PAP use for lipid-lowering therapy was associated with significantly higher medication adherence compared with patients who faced standard out-of-pocket costs (PDC 0.78 vs. 0.61, P<0.001) 7.

Uninsured Patients: Additional Resources

Uninsured patients who do not qualify for the Sanofi PAP may find alirocumab covered under state pharmaceutical assistance programs or through federally qualified health center (FQHC) 340B pricing. The 340B Drug Pricing Program allows eligible health centers to purchase outpatient drugs at significantly reduced cost, which can be passed to uninsured or underinsured patients 8. Ask your prescribing clinic whether they participate in 340B.

The Bridge Program: Covering the Prior Authorization Gap

The bridge program is the most time-sensitive of the three mechanisms. It activates when a prior authorization has been submitted but a coverage decision has not yet been issued, or when an initial denial is being appealed.

How to Trigger the Bridge

The prescriber or their staff contacts Praluent360 (1-844-PRALUENT) and certifies that a prior authorization is in process. Regeneron/Sanofi typically ships a 30-day supply within 3 to 5 business days. A second 30-day bridge shipment may be authorized if the PA decision is still pending. Some specialty pharmacies initiate the bridge request automatically when they detect a PA hold in the system.

Typical Bridge Duration and Quantity

Most bridge programs for Praluent provide one or two 30-day supplies (two or four auto-injectors, depending on the prescribed dose). At the 75 mg every-2-weeks dose, a 30-day supply contains two pens. At the 150 mg every-2-weeks dose or the 300 mg monthly dose, quantities differ accordingly. The FDA-approved dosing range for alirocumab spans 75 mg to 150 mg every 2 weeks, with the option to up-titrate after 4 to 8 weeks if LDL-C remains above target 9.

What Happens After the Bridge Ends

If the prior authorization is approved during the bridge period, the patient transitions to insurance-covered fills. If the PA is denied, the prescriber should escalate to a peer-to-peer review with the medical director of the insurer, then to a formal internal appeal, and finally to an external independent review organization if available. During each of those stages, additional bridge supply may be requested. The AHA/ACC 2022 Guideline on Chest Pain explicitly recommends clinician-led PA appeals for guideline-directed medical therapy 10.

Prior Authorization Strategy: Maximizing Approval Odds

A strong prior authorization submission is the single most effective way to minimize the time a patient spends on bridge supply.

Required Documentation for PCSK9 Inhibitor PA

Most commercial insurers require documentation of all of the following before approving a PCSK9 inhibitor. First, the patient must have a confirmed diagnosis of heterozygous familial hypercholesterolemia (HeFH) or established ASCVD 11. Second, the patient must have tried and tolerated, or documented intolerance to, at least two statins at maximally tolerated doses. Third, the patient must have added ezetimibe (unless contraindicated or intolerant). Fourth, an LDL-C level above the insurer's threshold, commonly 70 mg/dL or 100 mg/dL depending on risk category, must be documented on the current regimen.

Genetic Testing and FH Documentation

Patients with HeFH may benefit from genetic confirmation. A pathogenic variant in LDLR, APOB, or PCSK9 substantially strengthens the prior authorization narrative. The Dutch Lipid Clinic Network (DLCN) score is a validated clinical scoring tool that can support HeFH diagnosis even without genetic testing 12. The DLCN is referenced in the European Society of Cardiology and European Atherosclerosis Society guidelines on dyslipidemia and is increasingly cited in US PA letters 13.

Statin Intolerance Documentation

Documenting statin intolerance requires more than a patient report of muscle aches. Ideally, the record should show at least two statin trials (different molecules) with documented myalgia, CK elevation, or other adverse effects, along with a rechallenge attempt and re-occurrence. A 2022 Cochrane review of statin intolerance found that true statin-induced muscle symptoms occurred in 7 to 29% of patients in observational studies but in only 4 to 5% in randomized controlled trials when blinded, suggesting nocebo effects confound many cases 14. Careful documentation of symptoms with and without medication strengthens the PA case considerably.

How to Get Praluent Cheaper: Additional Discount Pathways

Beyond manufacturer programs, several additional mechanisms may reduce Praluent's cost.

Specialty Pharmacy Contracting

Some specialty pharmacies negotiate rebate arrangements directly with Sanofi/Regeneron that reduce net cost to the plan, which may translate to lower patient cost-sharing. Accredo (Express Scripts), CVS Specialty, and Walgreens Specialty are the three largest specialty pharmacy dispensers of PCSK9 inhibitors in the US. Patients should confirm that their specialty pharmacy of choice is in-network with their plan before the first fill 15.

Medicare Part D Options

Medicare patients are excluded from manufacturer copay cards under the Anti-Kickback Statute. However, beginning in 2025, the Inflation Reduction Act (IRA) capped out-of-pocket drug costs under Medicare Part D at $2,000 per year and eliminated the coverage gap ("donut hole") 16. For a drug with a $6,400 annual list price, this cap is highly meaningful. Medicare beneficiaries should also check whether their plan has a preferred PCSK9 inhibitor tier; in some D plans, evolocumab (Repatha) may be on a lower tier than alirocumab, or vice versa.

State Pharmaceutical Assistance Programs

More than 30 states operate pharmaceutical assistance programs for residents who exceed Medicaid income limits but still face high drug costs. Eligibility criteria and benefit levels vary widely. The National Conference of State Legislatures maintains a regularly updated database 17. Patients in New Jersey (PAAD), New York (EPIC), and Pennsylvania (PACE) have historically had access to PCSK9 inhibitor coverage through these programs.

Alirocumab vs. Evolocumab: Does the Choice Affect Access?

Both PCSK9 inhibitors on the US market, alirocumab (Praluent) and evolocumab (Repatha), have similar clinical profiles. ODYSSEY OUTCOMES 4 for alirocumab and FOURIER (N=27,564) for evolocumab both showed significant MACE reduction in high-risk patients, with hazard ratios of 0.85 and 0.85 respectively 18. The choice between them often comes down entirely to formulary placement and which manufacturer's access program is easier to manage for a specific practice.

When to Consider Switching Molecules for Access Reasons

If a patient's insurer consistently denies alirocumab but has evolocumab on a preferred tier, switching molecules is clinically reasonable. Both drugs achieve similar LDL-C reduction and both have demonstrated cardiovascular outcome benefit. The ACC/AHA 2022 Guideline on Lipid Management does not preferentially recommend one PCSK9 inhibitor over the other 19. A switch request to the prescriber with a note documenting formulary preference is typically sufficient.

Monitoring LDL-C and Adjusting Dose During the Access Process

LDL-C should be checked 4 to 12 weeks after starting alirocumab to confirm response. If LDL-C remains above the patient's target on 75 mg every 2 weeks, up-titration to 150 mg every 2 weeks is appropriate per the FDA label 9. During bridge periods, maintaining the prescribed dose is important because subtherapeutic dosing would undermine the PA justification narrative that the drug is effective for this patient.

Target LDL-C Values by Risk Category

The ACC/AHA 2018 Cholesterol Guideline recommends an LDL-C target of <70 mg/dL for very high-risk ASCVD patients and <55 mg/dL for those with multiple major ASCVD events or additional high-risk conditions 20. A baseline LDL-C well above these thresholds, documented before starting alirocumab, strengthens both the initial PA and any appeal.

Safety and Tolerability During Bridge Fills

Alirocumab is well tolerated. In ODYSSEY OUTCOMES, injection-site reactions occurred in 3.8% of patients on alirocumab vs. 2.1% on placebo 4. Neurocognitive adverse events were reported at low rates in both arms and were not statistically different. The FDA label does not require routine laboratory monitoring beyond lipid panels 9. Patients should be counseled to rotate injection sites and store pens in the refrigerator at 36 to 46°F (2 to 8°C), or at room temperature for up to 30 days if needed.

Can I Use HSA or FSA for Praluent?

Yes. Alirocumab qualifies as an eligible medical expense under IRS Publication 502, which covers prescription drugs used to treat a medical condition 21. Patients with a Health Savings Account (HSA) or a Flexible Spending Account (FSA) may use those funds to pay for Praluent copays, deductible-phase costs, or out-of-pocket amounts not covered by the manufacturer copay card. HSA funds roll over year to year, so accumulating HSA contributions to offset a high-deductible-year cost is a legitimate planning strategy.

HSA + Copay Card Stacking

The IRS does not prohibit using an HSA to pay the residual balance after a manufacturer copay card reduces the initial cost. The copay card covers one portion; HSA funds cover any remainder. This stacking strategy can effectively bring net patient cost to $0 in many cases. However, patients should confirm with their benefits administrator that their specific plan allows this arrangement, as some FSA administrators have differing interpretations of cost-sharing definitions.